UNSPSC 51433806: Cilazapril anhydrous

This classification denotes an ace inhibitor with the molecular formula C22H31N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Q9454114Q, chemically known as 6h-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid, 9-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)octahydro-10-oxo-, monohydrate, (1s-(1.alpha.,9.alpha.(r*))), but more generally known as cilazapril anhydrous, which bears US NIH Compound Identifier 56330.

UNSPSC 51433806 Cilazapril anhydrous is a Commodity code for a specific antihypertensive pharmaceutical agent, but state and local procurement activity under this code shows minimal direct relevance. The most recent opportunities in the source involve advanced life support medications (epinephrine, labetalol, adenosine, diltiazem) for emergency medical services, generic multi-source pharmaceuticals through cooperative purchasing, and direct-to-manufacturer prescription programs — none of which specifically name cilazapril or focus on this individual drug product. State and local governments procuring pharmaceuticals do so primarily through emergency services departments (fire rescue), health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions and therapeutic categories rather than contracting for individual active pharmaceutical ingredients.

Recent activity centers on three issuing bodies: the City of Tampa's Purchasing Department (soliciting advanced life support medications for Tampa Fire Rescue via sealed bid), the Texas Health and Human Services Commission (conducting exploratory market research for a direct-to-manufacturer prescription program), and the Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration, which issued an RFP for generic multi-source pharmaceuticals and OTC products effective July 1, 2026. The Tampa bid (26P00188, due April 8, 2026, estimated value $40,000) specified four medication line items with nine-month minimum shelf life and included a 5 percent SLBE bid discount. The MMCAP RFP (S1070000015802, due March 26, 2026) sought manufacturers to supply products through three authorized wholesalers with a two-year contract term and 3 percent administrative fee. No recent solicitations explicitly demand cilazapril anhydrous by UNSPSC code or drug name, and the code shows no clear pattern of state and local purchasing activity tied to this specific pharmaceutical product.